Abstract
Intracerebroventricular administration (6 micrograms/2 microliters) of D-2-amino-5-phosphonovalerate (AP-5), a specific antagonist of the NMDA receptors, prior to training impaired the passive avoidance in a retention test in rat. Pretreatment with oxiracetam and D-pyroglutamic acid at doses ranging from 50 to 500 mg/kg SC dose-dependently prevented the disruptive effect of AP-5. This finding indicates that an interaction with excitatory amino acid NMDA type receptors may be important in behavioural effects of the two pyrrolidinone derivatives.
MeSH terms
-
Animals
-
Avoidance Learning / drug effects*
-
Injections, Intraventricular
-
Male
-
Motor Activity / drug effects
-
Pyrrolidines / pharmacology*
-
Pyrrolidinones / pharmacology*
-
Pyrrolidonecarboxylic Acid / pharmacology*
-
Rats
-
Rats, Inbred Strains
-
Receptors, N-Methyl-D-Aspartate
-
Receptors, Neurotransmitter / drug effects*
-
Valine / analogs & derivatives*
-
Valine / antagonists & inhibitors
-
Valine / pharmacology
Substances
-
Pyrrolidines
-
Pyrrolidinones
-
Receptors, N-Methyl-D-Aspartate
-
Receptors, Neurotransmitter
-
2-amino-5-phosphopentanoic acid
-
Valine
-
oxiracetam
-
Pyrrolidonecarboxylic Acid